Agents such as DNMT inhibitors (e.g., azacytidine, decitabine) and HDAC inhibitors (e.g., entinostat, panobinostat) are being investigated for their capacity to reverse gene silencing and sensitize HCC cells to chemotherapy and immunotherapy (Lin et al., 2025; Tian et al., 2013). The gene discussed is DNMT1; the disease is hepatocellular carcinoma.